Switch theme
Sign up to access all valuation multiples
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
2000
81
LTM Revenue $1.7M
LTM EBITDA n/a
$670M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Chimerix has a last 12-month revenue of $1.7M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Chimerix achieved revenue of $0.2M and an EBITDA of -$96.5M.
Chimerix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Chimerix valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.3M | $0.2M | XXX | XXX | XXX |
| Gross Profit | $33.4M | $0.3M | XXX | XXX | XXX |
| Gross Margin | 10302% | 153% | XXX | XXX | XXX |
| EBITDA | -$93.0M | -$96.5M | XXX | XXX | XXX |
| EBITDA Margin | -28696% | -45506% | XXX | XXX | XXX |
| Net Profit | $172M | -$82.1M | XXX | XXX | XXX |
| Net Margin | 53138% | -38724% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Chimerix's stock price is $9.
Chimerix has current market cap of $801M, and EV of $670M.
See Chimerix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $670M | $801M | XXX | XXX | XXX | XXX | $-0.97 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Chimerix has market cap of $801M and EV of $670M.
Chimerix's trades at 382.8x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Chimerix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Chimerix and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $670M | XXX | XXX | XXX |
| EV/Revenue | 3159.9x | XXX | XXX | XXX |
| EV/EBITDA | -6.9x | XXX | XXX | XXX |
| P/E | -9.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -8.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpChimerix's NTM/LTM revenue growth is 1201%
Chimerix's revenue per employee for the last fiscal year averaged $3K, while opex per employee averaged $1.2M for the same period.
Over next 12 months, Chimerix's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Chimerix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Chimerix and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -35% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -45506% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -44306% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $3K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 10474% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 35176% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 45650% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chimerix acquired XXX companies to date.
Last acquisition by Chimerix was XXXXXXXX, XXXXX XXXXX XXXXXX . Chimerix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Chimerix founded? | Chimerix was founded in 2000. |
| Where is Chimerix headquartered? | Chimerix is headquartered in United States of America. |
| How many employees does Chimerix have? | As of today, Chimerix has 81 employees. |
| Who is the CEO of Chimerix? | Chimerix's CEO is Mr. Michael T. Andriole. |
| Is Chimerix publicy listed? | Yes, Chimerix is a public company listed on NAS. |
| What is the stock symbol of Chimerix? | Chimerix trades under CMRX ticker. |
| When did Chimerix go public? | Chimerix went public in 2013. |
| Who are competitors of Chimerix? | Similar companies to Chimerix include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Chimerix? | Chimerix's current market cap is $801M |
| What is the current revenue of Chimerix? | Chimerix's last 12-month revenue is $1.7M. |
| What is the current EV/Revenue multiple of Chimerix? | Current revenue multiple of Chimerix is 382.8x. |
| What is the current revenue growth of Chimerix? | Chimerix revenue growth between 2023 and 2024 was -35%. |
| Is Chimerix profitable? | Yes, Chimerix is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
